Karyopharm Therapeutics Inc.

Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to Carryform Therapeutics' third quarter 2024 financial results conference call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Alhan Webb, Senior Vice President, Investor Relations. Please go ahead.

Thank you, and thank you all for joining us on today's conference call to discuss Kero Farms' third quarter 2024 financial results and recent company progress. We issued a press release this morning detailing our financial results for the third quarter 2024. This release, along with a slide presentation that we'll reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohani, and Mike, who will provide an update on our results for the third quarter 2024 and recent clinical development. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements, FLS, for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995, outlined on slide three. Actual results may differ materially from those indicated by these FLS as a result of various important factors, including those discussed in the risk factors section of our most recent form 10Q, which is on file with the SEC and in other filings that we may make with the SEC in the future. Any FLS represents our views as of today only. While we may elect to update these FLS at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these FLS as representing our views as of any later date. I will now turn the call over to Richard. Please turn to slide four.

Good morning. Thank you, Elhan, and thank you all for joining us today for CarioFarm's Q3 2024 earnings call. Turning to slide five, I want to begin with the exciting news that we shared last week regarding our phase three Sentry trial in myelofibrosis. We announced a very favorable regulatory update as we are changing the co-primary endpoint of Sentry to Absolute TSS following productive discussions with the FDA. Absolute TSS is supported by leading investigators and patient advocacy organization, and increases our overall confidence in our trial. We remain on track to report top-line data from Century in the second half of next year. Cell and XOR's unique mechanism of action, compelling data, our targeted approach to clinical development, and ongoing disciplined cost management position us well to advance our prioritized late-stage pipeline which may enable two transformative opportunities as we build on our multiple myeloma foundation. With our existing commercialization capabilities, we are pleased to deliver our third consecutive quarter of net product revenue growth in the U.S. and are on track to deliver revenue in the upper half of the guidance outlined at the start of the year. Our established commercial organization is well set up to potentially drive successful and rapid launches in myelofibrosis and endometrial cancer. Turning to slide six, in myelofibrosis, if the data from our phase three sensory trial is supportive, we believe we will have the opportunity to transform the treatment paradigm by providing the first combination therapy in JAK-naive myelofibrosis. While ruxolitinib alone has remained the standard of care for over a decade, less than half of all patients achieve meaningful spleen reduction. We believe that combination therapy with a novel mechanism of action like XPO1 inhibition holds the key for driving rapid, deep, and durable responses for the vast majority of myofibrosis patients. We continue to estimate that our annual U.S. peak revenue opportunity of myofibrosis is approximately $1 billion in the multibillion-dollar myofibrosis market. In endometrial cancer, the opportunity remains substantial given the evolution in the molecularly-driven therapies. Our data in TP53 wild-type endometrial cancer offers the potential of a meaningful and unique mechanism in maintenance therapy for approximately half of all endometrial cancer patients. This represents approximately a billion dollars annual U.S. peak revenue opportunity as well. So, Hanya and Reshma will expand in detail on both these near-term transformative opportunities. Now, I'd like to turn the call over to Reshma, who will give an update on our clinical programs. Reshma?

Thank you, Richard. Turning to slide eight, I want to highlight the unique potential of our promising late-stage pipeline led by our three ongoing phase three studies. PerioPharm has the potential to establish new standards of care in solid and hematologic malignancies, building upon our foundation in multiple myeloma, while also optimizing the patient experience by incorporating substantially lower doses of selenexor in these studies. Beginning with myelofibrosis on slide 10, selenexor is a novel inhibitor of XPO1 that prevents the nuclear export of various proteins and messenger RNA molecules. By doing so, it promotes the nuclear localization and activation of important tumor suppressor pathways, such as P53, while concurrently inhibiting the cytoplasmic activation of various proliferative and profibrotic pathways linked to myelofibrosis pathobiology. In addition to these multiple pathways, position selenexor is a unique potential therapeutic option in myelofibrosis. Before highlighting our important update to the co-primary endpoint relating to total symptom score, I will recap efficacy and safety data observed from the phase one trial evaluating selenexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis patients as outlined on slide 11. Amongst the 14 patients who received selenexor 60 milligrams plus ruxolitinib, all evaluable patients achieved an SVR 35 at any time, And 79% of patients achieved SBR35 at week 24 in the ITT population. As you've heard from some of the leading physicians in this space on our call last week, clean volume reduction is viewed as one of the most important factors by treating physicians, given its correlation to overall survival. Having nearly 80% of patients achieve SBR35 is viewed as very positive. Durability of response is also a key efficacy measure relevant to JAK-naive patients. Our phase one data demonstrates a 100% probability of continuing response for both SBR35 and PSS50 as shown on slide 12 over a median duration of follow-up of 32 weeks and 51 weeks respectively. This is particularly meaningful as it suggests that once patients experience a response, they remain in response. On our call last week, one of the KOLs indicated that this is why he believes treatment of selenexor should be added to ruxolitinib early on in the treatment journey, given his view that deep responses early on are important and can improve outcomes for patients. Turning to slide 13, we were very pleased to announce last week that absolute total symptom score will replace PSS50 as a co-primary endpoint in our Century Phase III trial in myelofibrosis. Assessing the average improvement in symptoms over 24 weeks has gained support from the FDA, investigators, and patient advocacy groups, and is a more sensitive method to assess symptom improvement in myelofibrosis. The combination of Selinexor and Ruxolitinib has demonstrated promising evidence of improvement in absolute total symptom scores in our phase one trial, and we look forward to utilizing this more comprehensive assessment of symptom improvement moving forward. Building on our impressive SCR35 results from our Phase 1 trial, changing our co-primary endpoint to absolute TSS further increases our overall confidence in the Sentry Phase 3 trial. And we look forward to potentially addressing a tremendous unmet need in myelofibrosis with this combination. On slide 14, the depth of symptom improvement with 60 milligrams of Selinexor plus Ruxolitinib in our Phase 1 trial, can be seen in comparison to historical data from ruxolitin and monotherapy. The average reduction, which signifies improvement, absolute TSS of 18.5 points with our combination compared favorably to the average 11 to 14 point reduction that has been observed with ruxolitin and belone in prior phase three clinical trials conducted by others. The rapid, deep, and durable findings observed with SCR35 is also observed with average TSS as seen on slide 15. These are new data we are presenting for the first time today. Specifically, in our phase one trial, selenoxor plus rexalitin have demonstrated rapid, deep, and sustained improvements in average TSS. These rapid improvements in symptoms are seen as early as week four, despite any side effects that the patients may experience from the treatment. These symptom improvements continue through week 24, demonstrating meaningful sustained symptom improvement for the entire six-month duration evaluated. For the adverse events experienced, the most common were GI side effects such as nausea, anemia, thrombocytopenia, and fatigue. And I think it is worth considering what we heard from our KOLs on GI side effects last week. These GI side effects are most common at the start of treatment, only last approximately two cycles, and can be effectively managed with anti-emetics. Given this well-documented profile, we believe patients and physicians can easily be educated around this profile, enabling patients to stay on treatment long term. which ultimately is what drives meaningful screen reduction and symptom improvement. In summary, slide 16 highlights why the combination of Selinexor and Ruxolitinib has the potential to become the new standard of care if the combination is approved. And as we have heard at our recent call with myelofibrosis physicians, the myelofibrosis community wants to adopt combination therapies which quickly lead to deep and durable screen reduction symptom improvement. Selenoxor's potential in myelofibrosis is strengthened by its well-established safety profile, as it has been administered to approximately 30,000 patients across multiple cancer indications. The low dose of 60 milligrams that is currently incorporated in the phase three trial suggests that Selenoxor has the potential to be a tolerable, convenient, once-leakly oral treatment, especially with the use of antiemetics during the first two cycles of treatment. Turning to slide 17, we have increased confidence with the favorable changes made to the SEMTRI trial. We've proactively increased the total sample size to approximately 350 patients to further increase the statistical powering. Given the strong enrollment, our expectations of top line data remain in the second half of 2025. Furthermore, the co-primary endpoint will change from TSS50 to absolute TSS. The two co-primary endpoints, SCR35 and absolute TFS, will be tested sequentially. SCR35 will be evaluated first, and if positive, the alpha will then be rolled down to absolute TFS. Shifting focus to endometrial cancer on slide 19, felonexor primarily functions by blocking the export of T53 from the nucleus to the cytoplasm. When p53 accumulates in the nucleus, it leads to disrupted DNA repair processes, cell cycle arrest, and increased apoptosis. This mechanism is underscored by the anti-tumor effects in p53-dependent tumors, specifically in endometrial cancer, and has the potential to be the first novel oral maintenance therapy for patients with CP53 wild-type endometrial cancer. As seen on slide 20, the P53 wild-type status continues to increase in relevance throughout the treatment landscape for advanced and recurrent endometrial cancer. Recently, the FDA approved checkpoint inhibitors in combination with chemotherapy, followed by maintenance therapy with checkpoint inhibitors for advanced recurrent endometrial cancer patients, regardless of MMR status. However, the efficacy in patients with MMR-proficient tumors is notably lower compared to those with MMR-deficient tumors, aligning with the mechanistic rationale for the effectiveness of checkpoint inhibitors in MMR-deficient solid tumors. Notably, patients with both MMR-proficient and T53 wild-type tumors make up approximately 50% of all advanced or recurrent endometrial cancer cases. On slide 21 in the SIENDO trial, exploratory subgroup data presented at ASCO revealed that selenoxor has the potential to provide promising outcomes for patients with p53 wild-type endometrial cancer, achieving a median PFS of 28.4 months compared to just 5.2 months for placebo, translating to a hazard ratio of 0.44. Looking more closely at the MMR proficient subgroup on slide 22, our ASCO data on Siendo showed Selinexor demonstrates an encouraging signal of long-term median PFS benefit of 39.5 months. This was substantially higher than the 4.9 months observed with placebo, corresponding to a hazard ratio of 0.36. Although we acknowledge the limitations of cross-trial comparison, It's important to note that the PFS improvement with Selinexor in the subgroup exceeds the median overall survival achieved by checkpoint inhibitors in MMR-proficient patients, emphasizing Selinexor's substantial efficacy for these individuals. The updated safety data in endometrial cancer patients from the Sander trial is displayed on slide 23. It's important to note that the adverse events associated with Selinexor were generally manageable and well-tolerated. nausea, vomiting, and diarrhea were the most frequently observed adverse events, regardless of grade. Grade three plus treatment emergent events were infrequent, with neutropenia, thrombocytopenia, and nausea being the most common. Notably, the prophylactic dual antiemetics were not required during the standard trial, whereas dual antiemetics are not only required in ECO42, but all of our phase three trials, including Centrate. which is why we anticipate the safety profile from our phase three trials will be substantially improved. On slide 24, we remain on track for top line data readout for our pivotal export EC042 phase three trial in early 2026. I remain encouraged with the potential of Selenexor to achieve clinically meaningful outcomes in the maintenance setting for patients with E53 wild type endometrial cancer. especially those with MMR-proficient tumors. Lastly, our Phase III EMN29 SPD trial is outlined on slide 26. This trial aims to address the unmet needs of patients with multiple myeloma by offering an all-oral triplet treatment option that could also benefit those undergoing pre- and post-T cell engaging therapy and builds on the positive progression-free survival data previously observed with SPD40. As we noted on our second quarter earnings call, we have worked with the sponsor of the trial, the European Myeloma Network, to amend the statistical analysis plan. We had a completed screening for the planned approximately 120 patients, and will provide an updated timeline for top line data following regulatory feedback. We are very excited for what the future holds for Keriopharm, working swiftly to progress our three pivotal phase three programs, fueled by increasingly compelling data. Selinexor could significantly benefit various patient populations facing substantial unmet needs and also enhance our currently improved indications in multiple myeloma. I will now turn the call to Sohanya to provide updates on our commercial results from this quarter. Thank you, Reshma, and good morning. On slide 28, I'll discuss our commercial highlights for the third quarter of 2024. Expobio net product revenue was $29.5 million, up 5% compared to our results in the second quarter. We are very pleased with our third consecutive quarter-over-quarter growth of Expobio U.S. revenues amidst a highly competitive marketplace and are well on track to deliver in the upper half of the guidance that we outlined at the start of the year. In Q3, Expovia revenues were driven by double-digit demand growth versus the prior quarter, powered by an increase in refills and partially offset by an increase in gross to net, largely due to a higher 340B book of business. We achieved strong demand growth quarter over quarter in the community, where Expovia tends to be used as a convenient oral and manageable option for patients as an earlier line of therapy or if the patients are unable to access a T cell therapy. We also delivered growth in demand in our academic setting as our use as a novel mechanism of action pre and post T cell therapies continues to increase. With our team's strong execution driving demand growth for Expovio year to date, we are confident in our ability to deliver on our revised full year 2024 U.S. Expovio net product revenue guidance range of $110 to $115 million. Now I'd like to turn to slide 29 and shift our focus towards milestones accomplished outside of the U.S. I am pleased with our momentum as we expand our global footprint with continued reimbursement and regulatory approvals for Selinexor across the world. In the third quarter, Expovia received reimbursement approvals in Italy and France and continue to expand its global footprint with additional regulatory approvals globally. Our commercial franchise continues to benefit an increasing number of multiple myeloma patients globally, and as a profitable business, serves as a critical driver in funding our pipeline. With our dedicated commercialization team and partners, We have the capabilities for strong launches in potential future indications. I'd like to now present in detail the potential market opportunity that we see for Selinexor in myelofibrosis and endometrial cancer, each amounting to approximately a billion dollars in potential annual U.S. peak revenues. Turning to slide 30, starting with myelofibrosis. As discussed by Reshma and on our call last week, Selinexor has the opportunity to transform the frontline treatment paradigm in myelofibrosis. There are no drug classes other than JAK inhibitors approved in the frontline, which presents a unique opportunity for an efficacious and tolerable new drug with a novel mechanism of action to improve current standard of care. As we look at the myelofibrosis market in detail, there are roughly 7,000 estimated incidences in the U.S., about 6,000 of which are patients with intermediate to high-risk myelofibrosis. Approximately three-quarters of these patients with baseline platelet counts of 100 or above make up the target patient population for selenexor combination therapy. Third-party market research conducted last year showed that 75% of physicians indicated their intent to adopt combination therapies as a frontline standard of care, replacing ruxolitinib monotherapy due to the potential of better efficacy with the combination. The survey results also showed a strong perception from physicians on the product profile of Selinexor in combination with ruxolitinib. We would anticipate strong demand at launch if approved, given our data to date showing Selenexor's ability to meaningfully improve spleen volume and symptom management when added to the current standard of care. Furthermore, we have an established commercial infrastructure in the hematology space, and about 80% overlap in community-based physicians who treat multiple myeloma and myelofibrosis. This gives us a tremendous opportunity to build a strong presence for Selinexor in the multi-billion myelofibrosis market with a potential annual U.S. peak revenue opportunity of approximately a billion dollars. Now I'd like to shift your attention to endometrial cancer on slide 31, which is an equally attractive opportunity for us. We are very encouraged by the potential for Selinexor to address a significant unmet need in key molecular subgroups. As we engage with key opinion leaders in this space, it is clear that they see the unmet need for a targeted treatment in unique molecular subgroups, including TP53 wild-type tumors. While frontline treatment options are emerging rapidly, a clear unmet need remains in the P53 wild-type and specifically PMMR subgroup. Looking now at the potential market in more detail, endometrial cancer is the most common gynecologic cancer in the US, with about 17,000 expected incidences in 2032, approximately 80% of which is expected to be PMMR and 20% DMMR. About 10,000 advanced or recurrent endometrial cancer patients are expected to have p53 wild-type status. With about two-thirds of patients expected to respond to their frontline chemotherapy, roughly over 6,000 patients would be eligible for Selinexor a potential novel and biomarker-specific oral maintenance therapy. In third-party market research, when U.S. physicians were shown multiple product profiles, Selinexor was the preferred regimen for 75% of patients with TP53 wild-type and PMMR status. With our strong commercial presence in community accounts with Expovio, We expect to have roughly 80% overlap in community-based oncologists who treat multiple myeloma and endometrial cancer. As a result, we expect a rapid potential launch of Selinexor and endometrial cancer if approved with a potential annual U.S. peak revenue opportunity of approximately a billion dollars. Now I'd like to turn the call over to Mike to give an update on our Q3 financial results.

Good morning, everyone, and thank you, Sohanya. Turning to our financials, since we issued a press release earlier today with the full financial results, I will just focus on the highlights, which are on slide 33. Total revenue for the third quarter of 2024 was $38.8 million compared to $36 million for the third quarter of 2023. Net U.S. Expobio revenue for the third quarter of 2024 was $29.5 million compared to $30.2 million for the third quarter of 2023. The gross to net discount for Expobio in the third quarter of 2024 was 31% as compared to 21% in the third quarter of 2023 and 29% in the second quarter of 2024. This increase was driven by increased 340B utilization and Medicare rebates. We expect GTN for the full year of 2024 to be approximately 30%. Our total expenses for the third quarter of 2024 were down year over year by 3% due to ongoing headcount reductions and other cost-saving measures, partially upset by our continued investment in our three ongoing phase three clinical trials. R&D expenses for the third quarter of 2024 were 36.1 million compared to 35.6 million for the third quarter of 2023. The increase in R&D expenses was primarily attributable to higher clinical trial costs related to ongoing pivotal Phase III trial in myelofibrosis. SG&A expenses for the third quarter of 2024 were $27.6 million compared to $30.8 million for the third quarter of 2023. The decrease in SG&A expenses was primarily due to ongoing cost reduction initiatives and lower headcount. Cash, cash equivalents, restricted cash and investments as of September 30, 2024, totaled $133.9 million, compared to $192.4 million as of December 31, 2023. Based on our current operating plans, we are narrowing our guidance for the full year of 2024 as follows. Total revenue expected to be in the range of $145 to $155 million, as compared to previous guidance of $145 to $169. U.S. Expovio net product revenue expected to be in the range of $110 to $115 million, as compared to previous guidance of $105 million to $120 million. R&D and SG&A expenses are expected to be in the range of $255 million to $265 million, which includes approximately $20 million of estimated non-cash stock-based compensation expense, as compared to previous guidance of $250 million to $265 million. And finally, we expect our existing cash, cash-to-columbian investments, the revenue we expect to generate from ExpoBioNet product sales and other licensed revenues, and ongoing discipline expense management and cost-saving measures will be sufficient to fund our planned operations into Q1 2026. Note that our cash runway does not include paying off the remaining 2025 convertible notes in our $25 million liquidity covenant under the new term loan. Taking into account the repayment of the 2025 convertible notes in the minimum liquidity covenant, carry-from-expects of cash, cash equivalents, and investments will be sufficient to fund its operations into the fourth quarter of 2025. We expect our 2025 operating incentives to be lower than 2024 to recognize the full-year benefits of our ongoing cost-saving initiatives. In summary, we are focused on the advancement of our three Phase III trials and driving commercial performance while continuing to be very diligent when allocating our resources. Before turning the call back to Richard, I'd like to extend my gratitude to everyone here at CarioFarm, our shareholders, and everyone that I've had the opportunity to interact with in this role. I'm proud of helping to bring Expovia to the market and offering people with multiple myeloma a new therapeutic option. And I continue to believe the company has very meaningful opportunities ahead, particularly in myelofibrosis and endometrial cancer. I'll now flip to slide 34 and turn the call over to Richard for some final thoughts. Richard?

Thank you, Mike. It goes without saying that we are so grateful for your leadership and service to KarioPharm over the last five and a half years. You've played a very important role in Expovio's launch in the U.S., our partnership with Manarini, and the debt refinancing that we announced earlier this year. We wish you the best of luck in your new professional endeavors. Now, as depicted on slide 35, several significant milestones are approaching for CaryoPharm in the near future. We are excited about our innovation and growth strategy, which offers transformative opportunities with our Phase III clinical trials in myofibrosis, and endometrial cancer while building on our Multimiloma Foundation. These trials have the potential to deliver new standards of care for patients and significantly advance our company as we work to deliver value for our shareholders. As we move forward, we will continue to work diligently towards unlocking the full potential of Salinexor and driving our next phase of growth. Thank you again for joining us today, and I would now like to ask the operator to open the call up to the Q&A portion of today's call. Operator?

Ladies and gentlemen, we will now begin the question and answer session. If you have a question, please press the star followed by the one in the touchdown bound. Questions will be taken in the order received. Should you wish to cancel your request, please press the star followed by the two. If you are using a speakerphone, please lift the handset before pressing any keys. Your first question is from Brian Abrams from RBC Capital Markets. Your line is now open.

Hi, good morning. Thanks for taking my questions, and best wishes to Mike as well in his future endeavors. Two quick ones from me, I guess. First, on the average total symptom score on slide 15 that you've shown, obviously, you know, pretty meaningful or a pretty notable reduction over that 24-week period. But I'm just wondering how the magnitude of that change is influencing your powering assumptions. And the reason I ask is I believe Palabrasib in its original open label phase two study on top of RUX showed at least a median absolute TSS improvement in that same 60% or so ballpark. and then ended up sort of just being on the cusp of statistical significance in a 400 plus patient phase three. I guess secondarily, on TSS50, is that still going to be a secondary endpoint in the Phase III study? And is that something that you think the FDA will still be looking at, at least to even observe some trends there as potentially supportive of approval? Or have the regulators completely shifted to really only focusing on absolute? Thanks.

Thanks, Brian, for the question. This is . So in terms of average TSS that you noted on slide 15, yeah, I think those are very meaningful data. You know, I'll just reiterate, as I did on our prepared remarks, you know, what those data show over time is that the average TSS substantially improves starting as early as week 24. And then you can see as the patients progress from week 4 to 24, you continue to see this decrement all the way to that average 18.5 reduction that we've reported as part of the absolute TSS. So it really reinforces this meaningful improvement, which again is signified by a reduction in that TSS score. You know, when we look at our powering assumptions, what we're looking at is the delta across the two arms, right? So the average or the absolute TSS is an average assessment of the change in TSS from baseline to week 24. In the manifest data, you know, they observed an approximately two-point difference across the two arms. It was not statistically significant. our data suggests that we could observe something that is far higher, well above two, if not double to four or above. So again, I think the data are strong, really shows a very meaningful improvement. When you translate the likelihood to a phase three, it really suggests that you can not only see statistical significance in that absolute TSS but a clinically meaningful result as well. In terms of your second question for TSS50, so, you know, we are in a very enviable position to replace TSS50 with absolute TSS. So, the co-primary endpoints, again, will be SVR35 followed by absolute TSS. We will not be evaluating TSS50. I think we are really seeing an evolution in terms of how we assess symptoms within a JAK-naive space. I think everybody is in alignment. And when I say everybody, I'm really talking about our KOLs, patient advocacy groups, certainly the regulatory agencies, that absolute TSS, which again looks at the average over time, is probably the more sensitive and they're comprehensive. to analyze these symptoms.

Really helpful. Thanks so much. Thanks Brian. Thank you.

Your next question is from Ed White from HC Wainwright. Your line is now open.

Good morning. Thanks for taking my questions. Congratulations on the new regulatory approvals outside of the US. I'm just wondering if you can give us an update of where you stand in the countries that we've already launched, how the launches are going, and an outlook outside the U.S. for 2025. Thanks, Ed.

I'll turn to Sohanya for that.

Hi, Ed. We continue to see approvals for reimbursement as well as regulatory approvals in the past quarter. And we're very pleased with the global expansion of Selinexor. If you compare to some of the U.S. launch experiences, they're starting in largely earlier lines of therapy versus you know, pentarefractory and that obviously they have some of the learnings in terms of anti-emetic, side effect management. And so as we look at, you know, 2025, we'll obviously provide guidance on total revenues on the Q4 2024 call. But with the ongoing reimbursement approval and launches this year, we anticipate royalties from XUS selling XOR revenues to increase in 2025. Now, in 2024, we achieved a majority of the major market reimbursement approvals. Therefore, we don't expect those to reoccur next year. Again, we'll provide more color on total revenue guidance on our Q424 call.

Okay, thanks. And just to dig down into the end of the industrial market, you know, I just wanted to get your thoughts on some of the challenges of entering a maintenance therapy market versus, you know, a treatment market and how the company is addressing that particular market on maintenance and getting patients to take the drug in a maintenance setting.

Yeah, we are thrilled about the opportunity to launch in endometrial cancer as a potential novel and biomarker-specific oral maintenance-only therapy. For a couple of different reasons. I think as you've seen the marketplace evolve rapidly, particularly in the past year, there continues to be a significant unmet need in specific molecular subgroups. And in our case, particularly focused on the P53 wild type and PMMR subgroups. And this is where our data, as Reshma has discussed, is most compelling. Now, as we look at our product profile as a maintenance therapy, it is a highly compelling profile as supported by our market research. As I mentioned, when U.S. physicians were shown multiple product profiles, Selinexo was the preferred regimen for a majority, 75% of patients with TP53 wild-type and PMMR status. So, you know, my belief is we have a potentially groundbreaking therapy in this maintenance space in a highly targeted subgroup with a compelling profile and a convenient oral therapy. Important to also reinforce that as a commercial team, we have very strong overlap with treating physicians both in the multiple myeloma space and the endometrial space in the community, which enables us to hit the ground running with our messaging on day of approval. So we're very excited about the potential opportunity to launch in this maintenance setting.

Okay, thanks for taking my questions. Thanks, Ed.

Thank you once again. That is star one. Should you wish to ask a question? And your next question is from Peter Lawson from Barclays. Your line is now open.

Great. Thanks so much. Thanks for taking the questions. I guess just initially on the quarter, Sonia, you've seen three quarters of quarter over quarter growth. And if you can make any comments about any underlying trends there, anything that was different from the last couple of quarters for that quarter-over-quarter growth and the mix between price and volume and then academic versus community settings. Thank you.

Thanks, Peter, for the question. We're very pleased with our three consecutive quarters of net revenue growth, very proud of the team for the resilience and success they have demonstrated, particularly in Q3 in driving double-digit demand growth quarter-over-quarter. As we look at some of the dynamics here in terms of settings of care in the community setting, we achieved strong growth quarter-over-quarter. This remains the majority of our business. About 60% of our business came from the community setting. Importantly, in Q3 as well, we did see an uptick in demand in our academic setting as well, quarter over quarter. And this is really driven by the body of evidence that we have worked hard to build in the past year around this concept of T-cell fitness and Selenaxor's potential ability to preserve the immune environment with respect to T-cell therapy. And as we look at this current year to date and our performance, our team is working hard to continue to drive demand and position Expovio as a flexible, combinable, manageable drug that allows for a class switch. Even though the marketplace is highly competitive, it's clear that we are in a space where a multi-mechanistic approach is increasingly needed for successful patient outcomes, and that's exactly where Cellin-XR comes in as a differentiated mechanism of action. So, again, very pleased with our performance this quarter. We've narrowed our guidance for the full year and feel confident in meeting that range.

Thank you. Freshman, just on the MMR-proficient patients, do you need any kind of alignment with the FDA around calling that out as a marker? And kind of how's enrollment going there?

Yeah, thanks, Peter. So no, we don't, largely because the patient population that we're targeting is P53 wild type. And that P53 wild type, I think, the regulatory agencies and the FDA particularly really appreciate is going to include multiple molecular subgroups, including MMR proficient. So, you know, there's no need to specifically call them out. You know, with that said, will we be looking at potential subgroups by MMR status? Yes, that's something that we will be considering. In terms of enrollment, enrollment is going well. We're certainly on track to report top line results in the early part of 2026. A lot of that is fueled by, again, just, I think, strong enthusiasm for the data. You know, as we presented at ASCO and then, you know, again, had an opportunity to present very recently at IGCS in Dublin, those data and specifically the benefit that Selinexor provides to P53 wild types is, you know, almost unprecedented, right? I mean, we are seeing in that P53 wild type subgroup a 28.4-month median PFS. If you specifically look in that subgroup who are both P53 wild type and MMR proficient, again, that PFS now climbs to 40 months, which, you know, I mentioned earlier on the prepared remarks, you know, frost trial limitations aside exceeds the overall survival that you see with the checkpoint inhibitors. So, strong enthusiasm about, you know, the trial largely due to the benefit that we are seeing with Selenoxor and, you know, the strong anticipation that these results are going to translate in our ongoing phase three.

Great. Thank you so much. Thanks, Peter.

Thank you. Your next question is from . Your line is now open.

Hi. Good morning. Thanks for taking the question, and all of our best wishes to you, Mike, as well, next steps. I was going to ask one on the ongoing multiple myeloma SPD phase three study. Just if you could talk about the powering assumptions of the new trial design, What else do you need to align with regulatory agencies to get the go-ahead there? And when do you anticipate you'll be able to clarify the timeline to data for the study?

Yeah, thanks so much, Maury, for the question. So, you know, what we were able to do is to really leverage the positively evolving data that we specifically observed with SPD40. The median PFF you know, as I mentioned previously, is substantially larger, longer than what we previously assumed. So that ability allows us to target not only a smaller number of total patients, and as you can see, sort of like from earlier's prepared remarks, we're now going to be targeting 120 patients as part of the ongoing trial, but it also allows us to reduce the total number of PFS events that's going to trigger that, you know, primary analysis for PFS without compromising any of the power that had already been built into the trial. So, you know, we don't specifically comment on our exact powering assumptions. With that said, in all of our phase threes, we power, you know, above 80%. This trial is no different. So, you know, again, that ability is just based upon, you know, our ability to leverage the positively evolving efficacy. In terms of alignment with the FDA, so the updated enrollment as well as the updated statistical assumptions were incorporated to an amendment, and that has been sent to the FDA. We expect, you know, any kind of feedback to be coming in the next few weeks at that time. we will update, you know, our top line results milestones accordingly.

Got it. Okay. And maybe one follow-up just for the myelofibrosis study. Study goes out to 24 weeks. Do patients continue on treatment and what's the likelihood that you'll have to have a longer term follow-up potentially going out to 48 weeks?

Yeah, so patients are going to continue on therapy well beyond 24 weeks. So the 24-week mark just indicates, you know, when that SVR and the absolute TSS are going to be analyzed. Patients are going to be continuing. We have multiple longitudinal endpoints that we are going to evaluate, including PFS, overall survival. In terms of long-term endpoints, You know, right now, based upon our discussions with the regulatory agencies, the key endpoints that are going to drive regulatory decisions are, again, week 24. We'll have the opportunity to provide longer-term data, but right now, we're really focused on that 24-week data for, again, regulatory decision making.

Got it. Okay.

Thanks for taking my questions. Thanks, Maury. Thank you. There are no further questions at this time.

Please proceed.

Thank you, operator, and thank you, everyone, for joining us today. You know, as we mentioned, as an organization, we are focused and excited about delivering our innovation and growth strategy, which offers transformative opportunities with our phase three clinical trials in myofibrosis and endometrial cancer as we build on our multiple myeloma foundation. These trials, we've heard the potential for them to really deliver new standards of care and significantly advance our company as we work to deliver value to shareholders. Once again, thank you for joining us today.

Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining me. We all disconnect our lines.